Disseminated varicella zoster in an immunocompromised patient: A case report

Raymond E. Kennedy, Narpinder Dhanoa, Kevin Frey

ABSTRACT

Introduction: Human herpes virus 3 (HHV-3) is a human-specific virus known to be the cause behind chicken pox and varicella zoster. Presentation of this virus can vary depending on the immune status of the host. Typically, a uniform rash in a single dermatomal distribution is all that manifests. Alternatively, as in our case, a widespread and painful vesicular rash can erupt causing significant impairment requiring hospitalization.

Case Report: An HIV-positive immunocompromised male presented with disseminated varicella zoster (VZV) despite adequate compliance with HAART therapy. The painful vesicles sporadically covered all areas of the body (feet, abdomen, back, face, etc.) and did not present in the classic dermatomal distribution found in immune competent hosts. Despite adequate therapy with a new combination HIV medication, the patient’s CD4 count had diminished and he was admitted for suspected disseminated varicella zoster. Polymerase chain reaction (PCR) was later able to confirm the diagnosis.

Conclusion: Varicella zoster can have varying presentations depending on the immune status of the host. In an immunocompromised state, such as in our patient, the presentation can be widespread and more severe. Early diagnosis with polymerase chain reaction (PCR) and treatment with anti-virals and analgesics is a top priority for the patient’s well-being and clinical outcome. In our case, early detection and treatment allowed only for a minimal duration of the disseminated virus with prompt recovery and discharge from the hospital. Further investigation of the virus’ interaction with medications, such as HAART therapy, that potentially alters the expression of the virus despite vaccination, as some studies suggest, could be beneficial.
Disseminated varicella zoster in an immunocompromised patient: A case report

Raymond E. Kennedy, Narpinder Dhanoa, Kevin Frey

ABSTRACT

Introduction: Human herpes virus 3 (HHV-3) is a human-specific virus known to be the cause behind chicken pox and varicella zoster. Presentation of this virus can vary depending on the immune status of the host. Typically, a uniform rash in a single dermatomal distribution is all that manifests. Alternatively, as in our case, a widespread and painful vesicular rash can erupt causing significant impairment requiring hospitalization. Case Report: An HIV-positive immunocompromised male presented with disseminated varicella zoster (VZV) despite adequate compliance with HAART therapy. The painful vesicles sporadically covered all areas of the body (feet, abdomen, back, face, etc.) and did not present in the classic dermatomal distribution found in immune competent hosts. Despite adequate therapy with a new combination HIV medication, the patient’s CD4 count had diminished and he was admitted for suspected disseminated varicella zoster. Polymerase chain reaction (PCR) was later able to confirm the diagnosis. Conclusion: Varicella zoster can have varying presentations depending on the immune status of the host. In an immunocompromised state, such as in our patient, the presentation can be widespread and more severe. Early diagnosis with polymerase chain reaction (PCR) and treatment with antivirals and analgesics is a top priority for the patient’s well-being and clinical outcome. In our case, early detection and treatment allowed only for a minimal duration of the disseminated virus with prompt recovery and discharge from the hospital. Further investigation of the virus’ interaction with medications, such as HAART therapy, that potentially alters the expression of the virus despite vaccination, as some studies suggest, could be beneficial.

Keywords: Anti-viral, Acyclovir, Disseminated, HAART, Herpes Zoster, HHV, Immunocompromised, Varicella zoster, VZV, Varicella

How to cite this article

Kennedy RE, Dhanoa N, Frey K. Disseminated varicella zoster in an immunocompromised patient: A case report. Int J Case Rep Images 2016;7(3):154–157.

Article ID: Z01201603CR10611RK

doi:10.5348/ijcri-201624-CR-10611

INTRODUCTION

Human herpes virus 3 (HHV-3) of the Herpesviridae family is an exclusively human virus that causes chicken pox and varicella zoster (also referred to as shingles) [1]. A
single serotype of a virus can have varying presentations depending on the immune status of the host. In immunocompromised hosts, varicella demonstrates a disseminated presentation rather than the classic dermatomal distribution. In our case, a young male with HIV presented with a wide-spread, disseminated case of VZV despite treatment with newer combination HIV multi-drug therapy. The patient’s CD4 count had dropped significantly since his diagnosis, and start of the multi-drug medication, increasing his susceptibility to opportunistic infections. A 2013 study showed that HAART therapy might have different effects on VZV depending on the duration of the treatment, which could potentially explain the presentation in our patient [2].

CASE REPORT

A 30-year-old male presented to the emergency department complaining of a painful rash. He was diagnosed with HIV three months prior to his admittance and was compliant at the time with HAART therapy taking Stribild (a combination of elvitegravir, cobicistat, emtricitabine and tenofovir). In addition, he was compliant with azithromycin and bactrim for prophylaxis.

The rash started on his forehead and, within 48 hours, had spread down his to neck, upper chest, and lower extremities. His latest CD4 count (obtained three months ago upon diagnosis) was 132 cells/mm$^3$ and viral load was 36 copies/mL. He had no recent sick contacts, and denied any tick bites, recent travel, fever, chills or nausea/vomiting.

Upon admission, laboratory findings showed: blood pressure 125/74 mmHg and pulse 91 bpm 1 Resp: 18 breaths/min, SaO2 98% on room air, temperature 36.4°C, white blood cell count $3 \times 10^9$/L, platelet $122 \times 10^3$/μL, absolute neutrophil count 1.5, CD4 count 65 cells/mm$^3$, viral load 1639 copies/mL. On physical examination, the rash was composed of small vesicles with surrounding erythema, and was painful to the touch. It was located mainly on the forehead (Figure 1), between the patient’s toes (Figure 2) and plantar aspect of the foot (Figure 3), with scattered lesions on his legs, back (Figure 4), and abdomen (Figure 5). The vesicular lesions appeared to be in varying stages with no umbilication. The patient was immediately started on intravenous acyclovir 10 mg/kg IV q8hr [3], placed in isolation, and was monitored for progression of the lesions into the mouth or eyes. Within 24–36 hours, half of the body lesions had begun to crust over with no newly forming lesions. After 48 hours of treatment, all of the lesions crusted without further vesicle progression.

DISCUSSION

Normally, VZV is a clinical diagnosis; however, laboratory diagnosis becomes necessary in cases of infection control, or immunocompromised patients such as this case [4]. Several days after admission and initial treatment, polymerase chain reaction (PCR)—the diagnostic treatment of choice—confirmed the presence of varicella zoster.

Varicella Zoster (VZV) is a member of the herpesviridae family (HHV-3) known to affect humans [5]. Depending on age, its presentation varies causing chicken pox in the young and shingles in the elderly. Once infected, the virus remains dormant in the dorsal root ganglion of nerves, only to be re-activated at a later time (typically along the dermatome for which it lay dormant).
In aging adults, or immunocompromised individuals, the body cannot suppress the virus and a reactivation of zoster can present as a widespread rash—referred to as disseminated. The level of the absolute CD4 count can also alter the severity of presentation in the immunocompromised state [6]. When this occurs, the painful lesions are diffuse, at varying stages of development, and affect all parts of the body.

Treatment is aimed at minimizing the patient’s pain and shortening the duration of the episode. Over-the-counter pain medications are typical first line treatment, but the use of anti-virals such as acyclovir and its derivatives may be necessary. In an immunocompromised patient, anti-virals can be used as primary treatment in the acute setting, as well as prophylaxis to prevent recurrent episodes.

**CONCLUSION**

Varicella zoster virus (VZV), a member of the *Herpesviridae* family, can vary in presentation depending on the patient’s age and immune status. Early detection and treatment with analgesics and antivirals is important to limit the pain and duration of each episode. In an immunocompromised patient, early treatment is even more imperative as the presentation is typically more severe. In our case, the clinical outcome was excellent due to the rapid diagnosis and treatment by the medical team.

********

**Acknowledgements**

Paloma Kennedy - Technical assistance and editing.

**Author Contributions**

Raymond Kennedy – Substantial contributions to conception and design, Acquisition of data, Analysis
REFERENCES

1. Pergam SA, Limaye AP, AST Infectious Diseases Community of Practice. Varicella zoster virus (VZV) in solid organ transplant recipients. Am J Transplant 2009 Dec;9 Suppl 4:S108–15.
2. Liu C, Wang C, Glesby MJ, et al. Effects of highly active antiretroviral therapy and its adherence on herpes zoster incidence: a longitudinal cohort study. AIDS Res Ther 2013 Dec 27;10(1):34.
3. Malkud S, Patil SM. Disseminated Cutaneous Herpes Zoster in a Patient with Uncontrolled Diabetes Mellitus. J Clin Diagn Res 2015 Jul;9(7):WD01–2.
4. Gershon AA, Gershon MD. Pathogenesis and current approaches to control of varicella-zoster virus infections. Clin Microbiol Rev 2013 Oct;26(4):728–43.
5. Levy O, Orange JS, Hibberd P, et al. Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. J Infect Dis 2003 Oct 1;188(7):948–53.
6. Kramer JM, LaRussa P, Tsai WC, et al. Disseminated vaccine strain varicella as the acquired immunodeficiency syndrome-defining illness in a previously undiagnosed child. Pediatrics 2001 Aug;108(2):E39.
Edorium Journals: An introduction

Edorium Journals Team

About Edorium Journals
Edorium Journals is a publisher of high-quality, open access, international scholarly journals covering subjects in basic sciences and clinical specialties and subspecialties.

Invitation for article submission
We sincerely invite you to submit your valuable research for publication to Edorium Journals.

But why should you publish with Edorium Journals?
In less than 10 words - we give you what no one does.

Vision of being the best
We have the vision of making our journals the best and the most authoritative journals in their respective specialties. We are working towards this goal every day of every week of every month of every year.

Exceptional services
We care for you, your work and your time. Our efficient, personalized and courteous services are a testimony to this.

Editorial Review
All manuscripts submitted to Edorium Journals undergo pre-processing review, first editorial review, peer review, second editorial review and finally third editorial review.

Peer Review
All manuscripts submitted to Edorium Journals undergo anonymous, double-blind, external peer review.

Early View version
Early View version of your manuscript will be published in the journal within 72 hours of final acceptance.

Manuscript status
From submission to publication of your article you will get regular updates (minimum six times) about status of your manuscripts directly in your email.

Our Commitment

Six weeks
You will get first decision on your manuscript within six weeks (42 days) of submission. If we fail to honor this by even one day, we will publish your manuscript free of charge.

Four weeks
After we receive page proofs, your manuscript will be published in the journal within four weeks (31 days). If we fail to honor this by even one day, we will publish your manuscript free of charge and refund you the full article publication charges you paid for your manuscript.

Most Favored Author program
Join this program and publish any number of articles free of charge for one to five years.

Favored Author program
One email is all it takes to become our favored author. You will not only get fee waivers but also get information and insights about scholarly publishing.

Institutional Membership program
Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in fees make their research accessible to all.

Our presence
We have some of the best designed publication formats. Our websites are very user friendly and enable you to do your work very easily with no hassle.

Something more...
We request you to have a look at our website to know more about us and our services.

We welcome you to interact with us, share with us, join us and of course publish with us.

Edorium Journals: On Web
Browse Journals

CONNECT WITH US

Edorium Journals et al.

This page is not a part of the published article. This page is an introduction to Edorium Journals and the publication services.